Featured Research

from universities, journals, and other organizations

Anti-TNFs found to reduce risk of acute coronary syndrome in rheumatoid arthritis patients

Date:
October 27, 2013
Source:
American College of Rheumatology (ACR)
Summary:
Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research.

Tumor necrosis factor inhibitor drugs (commonly called Anti-TNFs) modestly reduce the risk of acute coronary syndrome, such as heart attacks and angina, in rheumatoid arthritis patients whose inflammation places them at higher risk of developing coronary heart disease, according to new research findings presented this week at the American College of Rheumatology Annual Meeting in San Diego.

Related Articles


Rheumatoid arthritis is a chronic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints are the principal body parts affected by RA, inflammation can develop in other organs as well. An estimated 1.3 million Americans have RA, and the disease typically affects women twice as often as men. High risk of coronary heart disease in RA patients has been linked to inflammation and disease severity, making effective management of these factors highly important.

Anti-tumor necrosis factor drugs are a class of drugs that have been used for more than 10 years. They are used worldwide to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, Crohn's colitis, ankylosing spondylitis and psoriasis. These drugs are able to reduce inflammation and stop disease progression.

Researchers in Sweden sought to determine if use of tumor necrosis factor inhibitor drugs to treat RA would result in a reduced risk of acute coronary syndrome (commonly called ACS), defined as a diagnosis of a heart attack or unstable angina (the worsening or increasing cardiac symptoms)

"As modern therapeutic alternatives in RA often make it possible to achieve a good control of joint inflammation, it is important to evaluate if this can also affect comorbidities," says Lotta Ljung, MD, senior consultant, rheumatology; Umea University Hospital; and lead investigator in the study. "Patients with RA have a doubled or so risk for acute coronary syndrome, and cardiovascular prevention is thus a major task for rheumatologists."

The researchers looked at the rates of coronary heart disease among RA patients using TNF inhibitors as compared to RA patients not using the drugs and the general population. The researchers identified a cohort of 7,704 RA patients from the Swedish Biologics Register with no previous incidence of ischemic heart disease who started their first TNF inhibitor between 2001 and 2010. The patients in this group were 75.9 percent female with an average age of 57.1 years. A comparator cohort of 23,112 matched, patients with RA who had never taken a biologic were identified from the National Patient Register. As a second comparator group, 38,520 matched individuals were randomly selected from the general population register.

Patient data was analyzed according to three periods of exposure to TNF inhibitors. "Actively" on TNF inhibitors was defined as taking the drugs until date of termination plus 90 days. "Short-term exposure" was defined as taking TNF inhibitors to two years. "Ever" was defined as having ever taken the medication. Acute coronary syndrome was defined as any primary discharge diagnosis of heart attack, unstable angina, or heart attack as cause of death from the Patient Register and the Cause-of-Death Register, respectively.

ACS occurred in the general population at a rate of 3.3/1,000 person-years, compared to 5.7 /1,000 person-years among those patients with RA actively on TNF inhibitor treatment and 8.6/1,000 person-years among those with RA who had never taken a biologic medication. Compared with the general population, and after controlling for confounding factors (such as disease duration, other co-existing diseases and socio-economic factors), patients with RA actively on TNF inhibitor treatment were 50 percent more likely to have ACS, while those who had never taken these medications were over twice as likely to have ACS. Compared to those who have never taken anti-TNF medication, the risk of ACS for patients actively on treatment was 27 percent lower. Similar risk estimates were observed in the other definitions of follow-up.

"This nationwide study adds to the evidence that use of TNF inhibitors for RA also has an impact on cardiovascular comorbidity," Dr. Ljung says. "Whether the lowered risk of ACS is attributable to the TNF inhibitors as such, or is an effect of better inflammatory control, cannot be determined from this study. The increase in risk of ACS in patients with RA was lower, but not abolished by the treatment. Therefore, individualized cardiovascular prevention is needed for most patients."


Story Source:

The above story is based on materials provided by American College of Rheumatology (ACR). Note: Materials may be edited for content and length.


Cite This Page:

American College of Rheumatology (ACR). "Anti-TNFs found to reduce risk of acute coronary syndrome in rheumatoid arthritis patients." ScienceDaily. ScienceDaily, 27 October 2013. <www.sciencedaily.com/releases/2013/10/131027122923.htm>.
American College of Rheumatology (ACR). (2013, October 27). Anti-TNFs found to reduce risk of acute coronary syndrome in rheumatoid arthritis patients. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/10/131027122923.htm
American College of Rheumatology (ACR). "Anti-TNFs found to reduce risk of acute coronary syndrome in rheumatoid arthritis patients." ScienceDaily. www.sciencedaily.com/releases/2013/10/131027122923.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins